Biological membranes in EV biogenesis, stability, uptake, and cargo transfer: an ISEV position paper arising from the ISEV membranes and EVs workshop


To link to this article: https://doi.org/10.1080/20013078.2019.1684862

© 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group on behalf of The International Society for Extracellular Vesicles.

Published online: 08 Nov 2019.
Biological membranes in EV biogenesis, stability, uptake, and cargo transfer: an ISEV position paper arising from the ISEV membranes and EVs workshop


Department of Molecular and Comparative Pathobiology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA; Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA; Department of Molecular and Translational Medicine, Università degli Studi di Brescia, CSGB and INSTM, Brescia, Italy; Molecular Genetics Division, CSIR-Indian Institute of Chemical Biology, Kolkata, India; Department of Medicine, School of Medicine, Cardiff, UK; Division of Pharmaceutics and Pharmacology, College of Pharmacy, Columbus, OH, USA; Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA; University of Virginia, Charlottesville, VA, USA; Exosome laboratory and Metabolomics Platform, CIC bioGUNE, CIBERehd, Bizkaia, Spain; IKERBASQUE, Basque Foundation for Science, Bizkaia, Spain; Laboratory of Epidemiology and Population Science, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA; Department of Microbiology and Immunology, Loyola University Chicago, Chicago, IL, USA; School of Biological and Health Science, Technological University Dublin, Dublin, Ireland; Department of Clinical Laboratory Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China; Fischell Department of Bioengineering, University of Maryland, College Park, MD, USA; Department of Psychiatry and Behavioral Neurobiology, The University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA; INSERM U939, Institut Curie, PSL Research University, France; Department of Pediatrics, University of California San Diego, La Jolla, CA, USA; Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway; Program in Molecular and Integrative Physiological Sciences Departments of Environmental Health, Genetics & Complex Diseases Harvard T.H. Chan School of Public Health, Boston, MA, USA; INBIRS Institute, UBA-CONICET School of Medicine University of Buenos Aires, Buenos Aires, Argentina; CNR Institute of Neuroscience, Milan, Italy; Cardiovascular Research Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA; K. G. Jebsen - Thrombosis Research and Expertise Center (TREC), Department of Clinical Medicine, UiT - The Arctic University of Norway, Tromsø, Norway; Department of Pathology, University of Washington School of Medicine, Seattle, WA, USA; Department of Chemistry, Shaw University, Raleigh, NC, USA; INSERM U1266, Hospital Saint-Anne, Université Descartes, Paris, France; VIB Center for Inflammation Research, Ghent, Belgium; Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium; Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC) CSIC-Universidad de Cantabria and Departamento de Fisiología y Farmacología, Universidad de Cantabria, Santander, Spain; Department of Biochemistry and Cell Biology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands; Rudolf Virchow Center, Julius-Maximilians-Universität Würzburg, Würzburg, Germany; School of Pharmaceutical Sciences, Tsinghua University-Peking University Joint Center for Life Sciences, Tsinghua University, Beijing, China; Department of Biological and Medical Sciences, Oxford Brookes University, Oxford, UK; Laboratory of Clinical Chemistry and Haematology & Department of Experimental Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands

ABSTRACT
Paracrine and endocrine roles have increasingly been ascribed to extracellular vesicles (EVs) generated by multicellular organisms. Central to the biogenesis, content, and function of EVs are their delimiting lipid bilayer membranes. To evaluate research progress on membranes and EVs, the International Society for Extracellular Vesicles (ISEV) conducted a workshop in March 2018 in Baltimore, Maryland, USA, bringing together key opinion leaders and hands-on researchers who were selected on the basis of submitted applications. The workshop was accompanied by two scientific surveys and covered four broad topics: EV biogenesis and release; EV uptake and fusion; and technologies and strategies used to study EV membranes; and EV transfer and functional assays. In this ISEV position paper, we synthesize the results of the workshop and the related surveys to outline important outstanding questions about EV membranes and describe areas of consensus. The workshop discussions and survey responses reveal that while much progress has been made in the field, there are still several concepts that divide opinion. Good consensus exists in some areas, including particular aspects of EV biogenesis, uptake and downstream signalling. Areas with little to no consensus include EV storage and stability, as well as whether and how EVs fuse with target cells. Further research is needed in these key areas, as a better understanding of membrane biology will contribute substantially towards advancing the field of extracellular vesicles.

CONTACT David Raul Francisco Carter, dcarter@brookes.ac.uk; Department of Biological and Medical Sciences, Oxford Brookes University, Gipsy Lane, Oxford, OX4 5BP, UK; Pieter Vader, pvader@umcutrecht.nl; Laboratory of Clinical Chemistry and Haematology & Department of Experimental Cardiology, University Medical Center Utrecht, Heidelberglaan 100, Utrecht 3584 CX, The Netherlands

ARTICLE HISTORY
Received 3 June 2019
Revised 23 August 2019
Accepted 4 October 2019

KEYWORDS
Extracellular vesicles; Exosomes; membranes; ISEV workshop; position paper; biogenesis; uptake; fusion; technology

© 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group on behalf of The International Society for Extracellular Vesicles. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Membranes are central to the identity and function of EVs. Specific lipids and membrane proteins in EVs may be used to reveal the cell type or the subcellular site of origin [27–29]. Bioactive lipids and integral or otherwise membrane-associated proteins may directly engage signalling pathways of cells and influence target cell-specificity of some EV populations [8]. Membrane-associated proteins also appear to be involved in EV uptake into cellular compartments, such as the endosomal/lysosomal system [30,31]. The EV membrane protects internal contents, mainly derived from the parent cell cytosol that may be transferred to recipient cells if EV-cell fusion occurs. From an experimental perspective, to show that EVs are present in a preparation, one must demonstrate the presence of an intact lipid bilayer that encloses cytosolic material [32,33] and maintains its integrity.

In order to reconcile and stimulate discussion on membranes and EVs, the International Society for Extracellular Vesicles (ISEV) conducted two targeted surveys and convened a workshop in March 2018 (Baltimore, MD) to collect and synthesize the input of EV and membrane biology scientists. The goal of this process was to gather expert opinions and define questions for future research. Four specific topics of interest, corresponding to four sessions and roundtable discussions at the Workshop, were; 1) the roles of membranes in EV biogenesis and release; 2) membranes and EV uptake and fusion; 3) technologies and strategies used to study EVs and membranes; and 4) EV functional transfer and functional assays (Text box 1). An overarching goal was to learn how better to utilize existing technologies for the study of

### Text Box 1. Roundtable topics, moderators, and descriptions.

**Roundtable #1: Biogenesis and Release**  
Moderators: Matias Ostrowski, Hang Yin, Roosmarijn Vandenbroucke  
EV subpopulations are commonly defined by site or mechanism of biogenesis. Roundtable 1 aimed to identify outstanding questions about how various molecules and pathways influence formation and release of EVs.

**Roundtable #2: Uptake and Fusion**  
Moderators: Pieter Vader, Jeanne Sisk, David Carter  
After release, EVs may exert effects through autocrine, paracrine, or endocrine processes, all of which require interaction of EV membranes with target cells. This roundtable focused on current knowledge of EV-cell interactions, including uptake and fusion, and experimental approaches needed to dissect mechanisms.

**Roundtable #3: Technologies and Strategies**  
Moderators: Marca Wauben, Paolo Bergese  
Since unique technologies and approaches may be needed to study EVs and their membranes, this roundtable discussion sought to identify technologies, experimental methods, and models that have not yet been well applied to EV studies or should be further developed to enable more sophisticated analysis of EVs and membranes.

**Roundtable #4: Transfer and Functional Assays**  
Moderators: Jan Lötvall, Daniel Anthony  
How EVs transfer cargo to recipient cells and how to assess effects of transfer were the considerations for this roundtable discussion. Also discussed were best practices for conducting and reporting EV studies (especially visualization), use of in vitro generated EVs for in vivo uptake studies, and the future of EV-based therapeutics.

*Because of substantial content overlap of Roundtable 4 with Roundtables 1–3, information from this roundtable has been integrated into other sections below.*

---

**Introduction**

Extracellular vesicles (EVs) are delimited by double-leaflet lipid membranes and released by cells of most, if not all, organisms. EVs remove waste components from the cell, can be used to share nutrition, and serve as cell-to-cell communicators by carrying and transferring bioactive enzymes and molecules and molecular information [1,2]. These mechanisms are important for normal homeostasis and regulatory functions, including development. EVs also play roles in disease processes, responding to and mediating inflammation and contributing to the development and progression of diseases [3–6]. These characteristics of EVs are also promising for theranostic applications [7–10], and for disease detection [11–18].

The generic term “EV” covers a broad range of vesicles [19], but it is not yet certain whether phenotypic heterogeneity is mirrored by functional heterogeneity. Two potential classes of EVs are determined by two major cellular sites of EV biogenesis [20,21]: the plasma membrane (PM) and the endosomal system. Although “exosome” was initially used for vesicles shed from the PM [22], the term was later adopted to specifically refer to intraluminal vesicles (ILVs) formed in the multivesicular body (MVB) that were released from the cell by fusion of the MVB with the PM [23–25]. In contrast, the terms “microvesicle,” “ectosome,” and “microparticle” are used to describe vesicles shed directly from the PM [26]. In addition to their biogenesis, EV subclasses may also be defined by size, shape, density, surface molecules, internal cargo, membrane components, cell type of origin, or function.
EV membranes, and to understand what novel techniques might be required. In addition to 55 junior and senior membrane biologists and engineers who contributed to the Workshop on-site, other ISEV scientists were in close communication with the organizers to ensure a balanced, interdisciplinary approach. This position paper was drafted to summarize current perceptions and opportunities as well as important questions in the study of EVs and their membranes. Areas of relative consensus are identified within the field, and areas where there is broader disagreement have also been highlighted. A number of specific recommendations are made for topics that require further study or technological development, which should help to focus and drive the field forward.

Membranes and EVs workshop pre- and post-surveys

An important part of the Workshop was gathering the opinion of experts who participated or were involved in the organization. Prior to the Workshop, a seven-question survey was circulated to planners and registrants to obtain opinions about the state of the field and identify outstanding questions (Table 1).

Following the Workshop, a 42-question survey was released to assess opinions post-Workshop using questions in a Likert-scale format: participants were asked to read a statement and rate on a scale of 0–10 whether they disagreed (0–4), agreed (6–10), or did not feel there was enough evidence to support or refute the statement (5). Participants were asked to refrain from entering responses for questions if they felt they lacked sufficient knowledge to answer. Three tables were constructed listing the survey questions pertaining to each overarching discussion topic: EV biogenesis, uptake, and technologies for studying EVs (Table 2–4).

Shown in Table 2 are 16 questions focusing on the fundamentals of EV biogenesis, the ways in which EV sub-populations are identified, the influence of membrane composition on EV biogenesis, and EV cargo packaging mechanisms. Table 3 outlines 16 questions used to gauge participants’ views on EV uptake, fusion, and stability. Ten questions pertaining to the necessity of novel assay development and the future of EV

Table 1. Workshop pre-survey questions.

<table>
<thead>
<tr>
<th>Pre-Workshop Survey Questions</th>
</tr>
</thead>
<tbody>
<tr>
<td>What, in your opinion, are the top publications (up to 3) in the last five years that have addressed important questions of EV/membrane biology?</td>
</tr>
<tr>
<td>What are the most pressing current questions in EV biogenesis? (Up to 4)</td>
</tr>
<tr>
<td>What important questions remain about EV component loading (natural or artificial) – this includes lipids, proteins, internal cargo? (Up to 4)</td>
</tr>
<tr>
<td>What are the most important unanswered questions about EV function as related to target cell interaction/uptake/fusion? (Up to 4)</td>
</tr>
<tr>
<td>To help answer outstanding EV/membrane questions, are there any technologies, methods, or models that have not yet been developed or fully applied? If so, what are they? Or what are the capabilities you would want? (Open response)</td>
</tr>
<tr>
<td>Do you have any position or opinion related to this workshop that you suspect some of your colleagues would disagree with? If so, what, what? (Up to 3)</td>
</tr>
<tr>
<td>Other comments or suggestions? (Open response)</td>
</tr>
</tbody>
</table>

Table 2. Survey questions regarding EV biogenesis.

<table>
<thead>
<tr>
<th>EV Biogenesis Survey Questions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Figure 1</strong> Budding into the multivesicular body (MVB) as intraluminal vesicles (ILVs) and budding from the plasma membrane are the two major EV biogenesis pathways, with at least partially independent molecular machinery of biogenesis. It is possible that what we refer to as MVBs are actually physical extensions of the plasma membrane and not late endosomes. It is currently possible to distinguish, using protein, lipid, or other markers, an “exosome” (former ILV in the MVB) from a “microvesicle” (from the plasma membrane) after the respective vesicle has left the cell. Size can be used to separate EVs by biogenesis pathway. EVs from the endosomal system are smaller, on average, than EVs that bud from the plasma membrane. We know the basic size distribution of EVs from biofluids and cell culture.</td>
</tr>
<tr>
<td><strong>Figure 2</strong> Excluding apoptotic bodies and other “macrovesicles”, the average diameter of most EV populations is: Significantly smaller than 100 nm Roughly in the 100–150 nm range Significantly larger than 150 nm</td>
</tr>
<tr>
<td><strong>Figure 3</strong> Asymmetric distribution of lipids (inner, outer leaflet) is the same in EVs as in the cell membrane of origin and remains stable over time. The inner and outer sides of the EV membrane are revealed by inner and outer domains of proteins in the expected orientation relative to the cell. That is, the cellular membrane topology is maintained by EVs.</td>
</tr>
<tr>
<td><strong>Figure 4</strong> The weight of the evidence supports preferential packaging of certain miRNAs or other RNA cargo into specific subsets of EVs. The RNA Cargo of larger EVs correlates with cellular expression, but that of small EVs does not.</td>
</tr>
<tr>
<td><strong>Figure 5</strong> It is possible to create cells or organisms that do not produce EVs. EV biogenesis is essential for life, as evidenced by lethality of TSG101 knockouts and knockouts of multiple biogenesis-linked proteins.</td>
</tr>
<tr>
<td><strong>Figure 6</strong> Lipid-raft domains (endosome-like domains, rich in cholesterol, etc.) play a role in EV biogenesis; without them, many EVs would not form. nSMase2 is not involved in biogenesis of all EV subtypes in all cells, hence discrepant results of nSMase2 blocking. Energetic requirements of EV biogenesis are largely unknown.</td>
</tr>
</tbody>
</table>
Table 3. Survey questions regarding EV uptake.

<table>
<thead>
<tr>
<th>EV Uptake Survey Questions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Figure 7</td>
</tr>
<tr>
<td>Figure 8</td>
</tr>
<tr>
<td>Figure 9</td>
</tr>
<tr>
<td>Figure 10</td>
</tr>
<tr>
<td>Figure 11</td>
</tr>
</tbody>
</table>

Table 4. Survey questions regarding current technologies for studying EVs.

<table>
<thead>
<tr>
<th>EV-Technology Survey Questions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Figure 12</td>
</tr>
<tr>
<td>Figure 13</td>
</tr>
<tr>
<td>Figure 14</td>
</tr>
<tr>
<td>Figure 15</td>
</tr>
</tbody>
</table>

Engineering are shown in Table 4. A summary of the responses, along with specific recommendations that emerged from the Workshop survey and discussions, is presented in Table 5. The table indicates areas of consensus, broad agreement, non-consensus, and recommendations for future EV research.

**EV biogenesis and release**

The Pre-Workshop survey returned many questions about biogenesis. Cell biology approaches have identified members of the endosomal sorting complex required for transport (ESCRT) pathway that contribute to EV biogenesis, but what are the requirements for these factors at different subcellular sites? Might molecular redundancies make it necessary to knock out or modulate multiple components of the biogenesis machinery to fully understand how EVs are formed? What about ESCRT-independent pathways? Do different biogenesis pathways give rise to vesicles with distinct functions, or conversely, does shared machinery at different locations (PM vs endosome) give rise to vesicles with comparable function? Another set of questions involves the molecular composition of released EVs. Do EVs released by a single cell have a diversity of form and function? What molecular associations are driven by proximity and random incorporation versus active loading, even energy-dependence? Do reports of specific incorporation of cargo molecules rely too much on non-physiologic experimental manipulations, or do they reflect physiologic realities? Some questions even addressed what
Table 5. Summary of topics on which there is largely agreement, relative consensus, or clear lack of consensus; a set of specific recommendations are included.

<table>
<thead>
<tr>
<th>Consensus</th>
<th>Most agree</th>
<th>No consensus</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biogenesis, size and content</td>
<td>Fusion of MVBs and budding from the PM are the main routes of EV biogenesis</td>
<td>It is not possible to distinguish microvesicles from exosomes using size, proteins, lipids or other markers, though most agree that MVs are on average larger</td>
<td>Most EV populations are &lt;100 or 100-150nm</td>
</tr>
<tr>
<td></td>
<td>EV biogenesis is essential for life</td>
<td>MVBs may actually be physical extensions of the plasma membrane and not late endosomes</td>
<td>Substantial additional work is required to identify specific markers of EV subtypes released across or within cell types</td>
</tr>
<tr>
<td></td>
<td>It is not possible to generate cells or animals that don’t produce any vesicles</td>
<td>RNA cargo of larger EVs shows better correlation with cellular expression compared to that of smaller EVs</td>
<td>Improved separation and characterization technologies are required for unbiased and accurate counting and sizing of EVs</td>
</tr>
<tr>
<td></td>
<td>The energetics of EV biogenesis are unknown</td>
<td>Asymmetry of lipids (in inner/outer leaflet) and proteins (orientation of proteins) is maintained relative to the cell</td>
<td>Reproducible in vitro assay systems which closely mimic the physiological context are needed to study EV cargo loading</td>
</tr>
<tr>
<td></td>
<td>Lipid rafts are important in EV biogenesis, and nSMase2 is not involved in the biogenesis of ALL EV subtypes</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>There is some specific loading of cargo into specific subsets of EVs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transfer, uptake and biodistribution</td>
<td>The apparent low rates of EV:cell fusion indicated by systems such as the Cre/lox stoplight system reflect the sensitivity and idiosyncrasies of the assay and do not imply that fusion is really so rare</td>
<td>Fusion is most likely to occur through endosomal uptake and acidification</td>
<td>EV:cell fusion events are rare, involving a minority subpopulation of EVs and specific uptake pathway</td>
</tr>
<tr>
<td></td>
<td>EV transfer experiments are time-dependent</td>
<td>Most cells eventually internalize at least some stained EVs</td>
<td>Greater understanding of how EVs induce their most important effects (direct interactions, transfer of different cargo etc) is needed</td>
</tr>
<tr>
<td></td>
<td>EVs accumulate in cancer tissue in xenografts because of vascular leakiness</td>
<td>EVs in vivo are bioactive; there is less consensus on whether EVs in circulation are bioactive, with most believing that EVs are most likely to have signalling functions locally within tissues</td>
<td>Serial or differential dosing may be necessary for in vivo studies aimed at understanding the function or biodistribution of EVs</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Proteins on the EV are required for fusion</td>
<td>Improved methodology, including imaging and staining, is required for the study of EV biodistribution</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The most significant interaction of EVs with cells is via signalling that occurs through proteins displayed on the target cell surface or in the endosomal lumen</td>
<td>There is a need for advanced animal models to study the physiological importance of EV-mediated cargo transfer between cells and tissue</td>
</tr>
<tr>
<td></td>
<td></td>
<td>It is possible to affect EV distribution to tissues by manipulating EV surface features</td>
<td>The field needs to establish guidelines for defining and/or concluding which EV subpopulations and associated cargo are involved in homeostatic maintenance and pathological responses</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Even studies in 2D culture systems are worthwhile as a representation of at least some aspects of in vivo uptake</td>
<td></td>
</tr>
<tr>
<td>Methodology</td>
<td>Dose-response studies are essential for establishing functions for EVs</td>
<td>Lipid dyes can form artefactual particles making results of experiments less reliable unless one can effectively separate these by flotation</td>
<td>It is possible to make EVs that faithfully mimic genuine EVs</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dose-dependency is a key factor to include in experimental design</td>
<td></td>
</tr>
</tbody>
</table>

(Continued)
how are EVs formed, and what are their defining characteristics?

A long-held assumption is that EVs form chiefly at two subcellular sites: the PM (microvesicles, ectosomes, microparticles), and the endosomal system/MVB (i.e. exosomes). Almost all survey respondents agreed to some extent with this concept (94%, Figure 1). ISEV standardization efforts suggest that multiple membrane-associated proteins should be measured to demonstrate the presence of the lipid bilayer and thus EVs. Beyond this necessary, yet general EV characterization, questions remain about the existence of biogenesis-specific membrane markers, and whether they can be generalized to EVs from many cell types. Several workshop participants suggested that EVs can be distinguished from PM-derived EVs by the presence of tetraspanin markers, such as CD61, CD63, CD81, ESCRT proteins, such as TSG101, and Alix, as well as syndecan, flotillin, and heat shock proteins. However, the subcellular distribution of these markers varied across cell types.

Size is also commonly used to distinguish EV subpopulations, following the assumption that exosomes are smaller than ectosomes. However, even if this assumption is valid for the average EV, small EVs might be called "limited" release, when some vesicles remain at or near the surface of the parent cell, held in place by tethering or adhesion proteins. These questions portray a field that has clearly taken large strides forward, but in which ample opportunities remain for additional discovery.

Based on the survey, six overarching questions were formulated to guide the roundtable discussion during the workshop. Consensus positions and additional research needs are presented in Sections 3.1–3.6.
(e.g. <100 nm in diameter) can be shed from the PM, and larger ILVs have been observed in MVBs, which could give rise to larger exosomes. Some groups have observed cell-type-specific differences in the size of ILVs in MVBs, further complicating the relationship between EV size and biogenesis. The majority (78%) of post-workshop survey respondents agree that size alone cannot be used to definitively categorize EV subpopulations (Figure 1). To further complicate matters, the field has not yet reached a consensus regarding the overall size distribution of EVs, as about half (48%) of the survey respondents believe that the average diameter is between 100 and 150 nm, while the other half (45%) believe it is less than 100 nm (Figure 2). This difference of opinion could arise from separation and characterization technologies that do not adequately recover or detect very small or very large EVs, or the employment of different techniques across laboratories. Recent technological advancements, such as the use of asymmetric flow field-flow fractionation for EV characterization, have revealed that some cell types release two distinct subpopulations of small EVs (sEVs; 60–80 nm and 90–120 nm), as well as a third population of small (~35 nm), non-membranous nanoparticles, referred to as “exomeres” [37].

The results of the survey confirm that to aid in our understanding of EV biogenesis, we must address several considerations. How are EVs different from their parent cell in terms of membrane architecture and cargo? Can we identify key regulators or signaling pathways necessary for biogenesis through the use of genetic manipulations? What are the physiological consequences of inhibiting EV biogenesis? What is the

Figure 1. EV Identification and size. Six questions regarding EV identification and sizing were administered in the post-workshop survey. For each question, participants’ answers are depicted horizontally on a Likert-scale from 0 to 10, with bubble size reflecting the number of responders at each point on the scale. Most responders believe that there are multiple distinct pathways for vesicle biogenesis that result in heterogeneity in terms of size. Identifying vesicles from these pathways based on size, protein or lipid markers remains difficult.
relative contribution (quantitatively) of PM vs MVB pathways for EV biogenesis? Researchers should consider the entire trafficking landscape of intracellular vesicular organelles which can directly, or indirectly affect EV biogenesis and secretion.

Does the topology of EV membrane lipids and proteins reflect that of the cell?

Phospholipids are distributed asymmetrically across cellular lipid bilayers, and intracellular compartments can differ in their lipid composition (e.g. differences in PM and MVB membranes). This distribution determines, among other things, curvature, and the fluidic and electrostatic properties of lipid membranes [38]. Phosphatidylserines (PS), phosphatidylethanolamines (PE), and phosphatidylinositolps (PI) are ubiquitous phospholipids located predominantly in the inner leaflet (cytosolic side) of the PM, due to the action of phospholipid flippases. Interestingly, PS and PE have been reported in the outer leaflet of EV membranes [35,39], which may be a by-product of their biogenesis and may be important for their function. PS exposure is known to serve as an “eat me” signal for engulfment and may, therefore, influence EV uptake. Workshop participants had contrasting opinions about whether EV phospholipid distribution mirrors that of the cell, and whether lipid distribution remains stable over time (Figure 3).

The majority of workshop participants (61%) suggested that the membrane topology of the cell is maintained in EVs (Figure 3). However, there is evidence that some EV membrane proteins have an “inside-out” topology [40]. Protease digestion assays, membrane permeabilization, and antibodies targeting outer or inner epitopes of specific membrane-associated EV proteins may be useful to investigate the topology and subcellular origin of specific EV proteins, and reveal whether this is a result of EV biogenesis or an artefact of EV purification methods.

How do membranes influence EV cargo loading or sorting?

Despite considerable interest, specific EV cargo sorting mechanisms are still unclear, although several have been proposed [41,42]. Ubiquitin-dependent ESCRT sorting mechanisms [43] and tetraspanin-enriched microdomains (TEMs) have been proposed to sort proteins into EVs [44]. Sorting of RNAs has also been postulated (reviewed in [45]). While the majority (61%) of Workshop survey respondents believe that the packaging of certain RNAs into EV subsets occurs (Figure 4), this is still an area of intense ongoing research. Conceptually, the larger the EV, the more likely it is to incorporate a given cytoplasmic entity, whereas sEV contents are more likely to be restricted to molecules in close proximity to membranes. This concept is supported by some data, such as the finding that large EVs (lEVs) and their parent cells have highly correlated RNA expression profiles, while RNA expression of sEVs differs significantly from that of the
Figure 3. EV membrane topology. Two questions regarding EV membrane topology were administered in the post-workshop survey. For each question, participants’ answers are depicted horizontally on a Likert-scale from 0 to 10, with bubble size reflecting the number of responders at each point on the scale. Responders are uncertain as to whether the lipid distribution of EV membranes is the same as the original cell membrane.

Figure 4. Membrane Involvement in EV Cargo Packaging. Two questions regarding the involvement of membranes in EV cargo packaging were administered in the Post-Workshop survey. For each question, participants’ answers are depicted horizontally on a Likert-scale from 0 to 10, with bubble size reflecting the number of responders at each point on the scale. Responders are not sure whether miRNA or RNA cargo is specific to certain subtypes of EVs.
source cell [46]. Likewise, larger cargo, such as full-length mRNAs with associated proteins, may not easily fit into sEVs without efficient packaging mechanisms. On the other hand, enveloped viruses can fit nucleic acids of up to 30 kb into vesicles of ~80 nm in diameter. Thus, size constraints apply, but perhaps the organization of the packaged materials is even more relevant.

Related to understanding how protein–RNA interactions may allow for specific cargo loading into EVs, standing questions in the field revolve around the involvement of ribonucleoproteins (RNP)s like Argonaute2 (Ago2) [47], ELAV-like protein 1/human antigen R (HuR) [45,48], and hnRNPA2B1 [49], and the sequence-specificity of effects. If RNA loading is sequence-specific, it may also be dependent on cell type and altered during stress conditions. Assessing physiological relevance is also important. For example, introducing high concentrations of highly purified proteins or synthetic RNAs into cell lysates may result in associations that are physiologically irrelevant, and/or induce off-target effects. Finally, perhaps not all EV “cargo” is contained inside the EV. RNA and DNA alike have been reported in association with the outside of the membrane as well; however, this may be an artefact of the isolation procedure [45]. The importance of developing reproducible in vitro assay systems to study EV cargo loading which closely mimics the physiological context cannot be overemphasized. Successful adaptation of such working models is recommended as it will help answer many questions related to the targeting and packaging of EV cargo molecules.

**Which proteins and lipids control EV biogenesis and secretion?**

Genetic or epigenetic manipulation has implicated several families of proteins in EV biogenesis and release, such as Rab GTPases, ARRDCl, and ESCRT complexes [50,51]. The Rab family of small GTPases plays a critical role in intracellular trafficking, and several Rabs, including Rab27a, Rab27b, Rab35, and Rab11, have been implicated in EV release [52–58]. In the case of exosomes, it should be considered that their release machinery will include both molecules affecting the formation of ILVs, the transport of MVBs to the PM, and the fusion of MVBs with the PM. In the case of microvesicles, the machinery includes proteins involved in trafficking to the PM, as well as factors at or in the PM [59]. ARRDCl mediates the release of a subpopulation of PM-derived EVs known as ARMMS (ARRDCl-mediated microvesicles) [60] and possibly endosome-derived EVs [61]. Gut explants from ARRDCl and ARRDCl knockout animals showed markedly reduced EV release [62], while in vitro over-expression of ARRDCl significantly increased EV secretion [63].

To what extent can knockout or knockdown of EV biogenesis proteins abrogate EV release, and what consequences does this have for the cell or organism? The majority (59%) of Workshop participants do not believe it is possible to create an organism or cell that does not produce any EVs (Figure 5). Knockout of TSG101 appears to be lethal in some models [64,65], as the protein is essential for many important cellular functions, such as endosomal receptor sorting independent of EV secretion [66]. Not all knockouts of EV proteins are lethal or produce overt phenotypes; however, the lack of overt phenotypic changes in a mouse does not necessarily equate with a lack of important function. For example, in vivo knockout of ARRDCl reduces EV plasma concentrations by ~50% in mice and confers no behavioural differences in normal settings; however, a phenotype may emerge after induction of non-physiological conditions. Overall, the data support the existence of independent and redundant biogenesis pathways with multiple components. Unbiased genetic screens and small molecule modulator screens may be needed to resolve unappreciated contributors to EV biogenesis. Similarly, manipulating multiple factors may be necessary to understand some mechanisms involved in EV biogenesis.

Aside from membrane proteins, lipids are also believed to influence EV formation. PE is thought to play a critical role in regulating membrane fusion and curvature, and therefore may be involved in EV biogenesis or function [35,59]. PI has also been implicated in EV release through one of its by-products. Hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) yields inositol trisphosphate (IP3) and diacylglycerol (DAG); DAG contributes to MVB formation, and to the secretion of EVs [67,68].

Sphingomyelin is a sphingolipid normally found in the outer leaflet of membranes (extracellular or luminal side). Enzymes such as neutral sphingomyelinase (nSMase) and acid sphingomyelinase (aSMase) convert sphingomyelin into phosphocholine and ceramide, which alters membrane fluidity and promotes microdomain formation. Interestingly, 62% of survey respondents believe that lipid rafts/microdomains contribute to the formation of vesicles [69,70] (Figure 6). nSMase inhibitors, such as GW4869, have been shown to significantly reduce small EV release from some [71], but not all systems [72], and even results in a compensatory increase in large EVs in some systems [73]. Conversely,
Figure 5. Importance of EVs for Life. Two questions regarding the importance of EVs for life were administered in the post-workshop survey. For each question, participants’ answers are depicted horizontally on a likert-scale from 0 to 10, with bubble size reflecting the number of responders at each point on the scale. The majority of responders believe that EV production is necessary for cell and organism survival.

Figure 6. Requirements for EV Biogenesis. Three questions regarding requirements for EV biogenesis were administered in the post-workshop survey. For each question, participants’ answers are depicted horizontally on a likert-scale from 0 to 10, with bubble size reflecting the number of responders at each point on the scale. Responders believe that the roles of lipid-raft domains, nSMase2, and the energetic requirements of EV biogenesis need to be further explored.
overexpressing nSMase2 increases ILV formation, which is thought to occur via an ESCRT-independent biogenesis pathway [71]. More than half (59%) of ISEV workshop participants doubted nSMase2 involvement in the biogenesis of all EV subtypes (Figure 6), but there is also evidence that aSMases are involved in EV release [74]. Thus, the roles of various sphingomyelinases, ceramide, and lipid rafts in EV biogenesis require further investigation.

**How are external signalling agents and membrane components involved in EV release?**

Beyond genetic manipulation, biogenesis pathways can be altered by external signals. For example, serotonin stimulates EV release from microglia [75], and histamine induces EV release from cervical carcinoma cells. Inflammatory signals generally alter EV release [76]. For example, dendritic cells exposed to lipopolysaccharide (LPS) produce significantly more, and more immunogenic EVs compared with non-exposed controls [77,78]. Exposure to dsDNA has also been shown to induce inflammation and EV release [79], and IgE-mediated mast cell activation leads to the rapid release of a distinct EV subset [27]. Despite low levels of constitutive EV release by B cells, upon stimulation via CD40 and IL4 receptor, EVs displaying MHCI, MHCII, and surface antibodies were released, likely participating in immune responses [80]. Similarly, stimulation of toll-like receptors (TLRs) induces the release of exosomes with pro-inflammatory activity [81]. Thus, EV biogenesis is also influenced by external factors.

**What are the energetic requirements of EV biogenesis?**

The field has yet to determine the energetic requirements for biogenesis and release of EVs. Is metabolic adaptation required to provide energy for EV secretion and/or precursors for the biosynthesis of the lipids, proteins, etc. that will be incorporated into EVs? Indeed, there are very few studies that show the relationship between cellular metabolism and EV release. One recent study suggests that EV secretion from tumour cells heavily relies on aerobic glycolysis [82]. Others have shown that activation of hypoxia-inducible factor-1α (HIF-1α) can induce transcription of both Rab22a [83] and Rab27a [84], and indirectly leads to increased EV secretion. Thus, metabolic regulators play an important role in EV production, and further research is needed to directly link metabolism and EV production.

**Contact, uptake, and fusion**

In the Pre-Workshop survey, planners and registrants were asked about outstanding questions regarding EV uptake and/or fusion. From the responses, one can clearly appreciate that this topic is greatly understood, as the field has yet to find answers to some basic questions. For example, it remains largely unclear how EVs interact with cells, and what dictates the next step (signalling, uptake or fusion) of the bound EVs. The molecular drivers (e.g. proteins, lipids, sugars, nucleic acids) of EV-cell interactions are largely unknown, including how these vary among cell types, with cell state, or among EV subtypes. What molecules or conditions drive EV endocytosis, and how do they affect EVs’ intracellular destination? Do EVs deliver their cargo into the cytosol after membrane fusion in a similar manner to viruses and if so, does this occur at the plasma membrane or an endosomal membrane? How often do fusion events occur and what determines this? Is the field focusing too much on fusion at the expense of lysosomal degradation or signalling, giving the perhaps false impression that fusion is the main fate of EVs and that cargo delivery to the cytosol is their most important role?

Based on this list of questions from the survey responders, we formulated four overarching questions that formed the basis of the roundtable discussion during the Workshop, and of the Post-Workshop survey. Consensus on these topics is presented in sections 4.1–4.4.

The most important unanswered questions about EV function focused mainly on EV tissue distribution and their ability to cross anatomic barriers, and on their true importance for life under physiological and pathological conditions. These questions were discussed during the roundtable on transfer and functional assays. Consensus on these topics based on this discussion and the Post-Workshop survey is presented in sections 4.5 and 4.6, and recommendations stemming from the survey and Workshop discussions are summarized in Table 5.

**What are the general mechanisms of cell-EV uptake?**

EVs might exert effects on cells by contact, uptake, fusion, degradation, or a combination of these modalities. As an example of each, “contact” would include interactions between EV surface proteins and cell surface proteins; “uptake” would be internalization of the EV into the endosomal system (for example); “fusion” would be fusion of EV and cellular membranes, with EV contents being released into the cell cytoplasm. The latter
might occur at the plasma membrane or only after “uptake.” While there are many reports demonstrating EV contact, endocytosis, and endolysosomal degradation, direct evidence for EV fusion with cellular membranes is scarce. General mechanisms for cell-EV uptake remain unclear, with many questions arising:

Is cellular uptake of EVs mediated by specific processing mechanisms? Is the primary purpose of EV uptake cellular communication and signalling, or is uptake just a byproduct of clearance or homeostatic mechanisms? Does uptake also confer function? Are there differential uptake pathways for different subpopulations of EVs (small vs large EVs)? Where do EVs go once they are endocytosed by individual cells; do they fuse with endo/lysosomal membranes to reach the cytoplasm, go to the ER [85], end up being degraded in lysosomes, or do something completely different? How is EV cargo unloaded into a cell? How does EV-based transfer of genetic material and cellular signals differ from that mediated by tunnelling nanotubes?

Three quarters of survey responders agreed that most cell types eventually internalize at least a proportion of EVs, seemingly regardless of the cell of origin (Figure 7). Despite the possibility of non-specific uptake, three-quarters of responders agreed that proteins on the EV surface are required for most fusion events between EVs and cellular membranes (Figure 7). Cells could also recognize lipids on the surface of the EVs, allowing for non-specific uptake or fusion events to occur. However, specificity likely determines many of the interactions between EVs and their target cells, so it is plausible that many of these interactions are mediated by receptor-ligand binding.

How specific are EV-cell interactions, and how can we experimentally investigate them?

The EV-cell interaction is likely a handshake: factors on the surface of both membranes contribute. Molecules exposed on the EV surface, including fibronectin, PS, and integrins, interact with heparan sulphate proteoglycans [86], T-cell immunoglobulin- and mucin-domain-containing molecules [87], and cell-associated extracellular matrix [8] present on recipient cells. Chemokines and their receptors may act as bridges linking the two membranes together, as they are expressed on both EVs and cells [88,89]. Although follicular dendritic cells do not express MHC-II, their surface can become fully decorated with vesicles that do (likely derived from B-cells) [90]. Additionally, the charge or reactivity of EVs, glycolipids on the EV surface, and even membrane curvature can all influence how EVs interact with certain recipient cells.

Survey participants were asked to rank several potential mechanisms of EV-cell interaction through which EVs exert their effects from the most (1) to least (5) likely (Figure 8). Signalling through membrane proteins was ranked as the most likely mechanism. The next two most likely mechanisms were considered to be the delivery of functional proteins and RNAs, respectively. Transfer of functional lipids and nutrition (molecular recycling) were the next most likely.

Certain conditions may need to be met before EV uptake can occur. For example, dendritic cell-derived EVs can only bind activated T-cells that express high-affinity LFA1 [91]. Cellular uptake of EVs may also be regulated by competitive mechanisms. For example, when working with unfractionated peripheral blood mononuclear cells (PBMC), MSC-EVs are mainly taken up by monocytes and only scarcely by T and NK cells; yet adding EVs to singularly cultured T or NK cells increases uptake significantly [92]. Furthermore, small and large EVs may have different membrane compositions that could give rise to divergent uptake mechanisms.

EV uptake in vivo also shows selectivity. Red blood cells are the most abundant cells in the body and produce a high number of EVs that contain unique miRNAs [93,94]. These EVs are only found in blood/serum and are usually not observed in the surrounding tissue. EVs present in the circulation and interstitial fluid of zebrafish are taken up only by endothelial cells and macrophages, but not muscle cells (despite being bathed in EVs) [95]. These observations support the notion that there are likely differential uptake mechanisms for EVs, depending on cell type and/or EV subpopulation.

Specific proteins or lipids that may prevent uptake in one cell type versus another by inhibiting docking, fusion, or internalization of EVs have not been identified. An interesting consideration is how the extracellular matrix (ECM) may influence EV processing or uptake in neighbouring cells. Unlike cell culture models, the in vivo ECM may contain proteins and proteases that contribute to or prevent EV uptake. As such, experiments conducted in vitro likely do not recapitulate in vivo uptake mechanisms accurately.

How do variables such as dose, time, pH, and temperature affect EV uptake?

“One dose does not fit all”. EV uptake by cells should be determined through specific, well-designed dose-dependent experiments. Comparison of dose-
dependent uptake profiles of human serum small EVs by murine and human cell lines showed that EVs from the same source could be internalized by one, several or all of the cell lines depending on the dose [96]. Therefore, considering a fixed EV dose for different target cell lines may entail misleading results.

With respect to time, EV uptake has been reported in as little as 15 min [87], which is consistent with endocytosis rates, while lysosomal degradation of EVs has been reported within hours [85,97]. If EV cargo is delivered to cells so rapidly, a rethink of days-long experiments after a single addition of EVs may, depending on the functional readout, be in order.

Considering pH, ILVs are formed in the acidic lumen of the MVB, so exosomal proteins should be somewhat pH resistant. Nevertheless, pH can alter EV interactions with cells. For example, some viral membrane fusion proteins are inactive at pH 7, but undergo conformational changes at pH 5, leading to membrane fusion [98]. An EV that has entered the endosomal pathway will also undergo progressive acidification. As a fusion of EVs and cellular membranes would lead to the delivery of the EV content into the cell cytoplasm [9], understanding how pH influences the cell–EV interactions is an interesting avenue of research that requires further work.

Regarding temperature, it was previously shown that EVs are taken up by cells at 37°C, but EVs can bind to the cell surface when endocytosis is blocked at 4°C [99,100]. Experimental manipulation of temperature might provide valuable mechanistic clues into EV uptake.

**Figure 7.** EV-cell fusion. Five questions regarding EV-cell fusion were administered in the post-workshop survey. For each question, participants’ answers are depicted horizontally on a Likert-scale from 0 to 10, with bubble size reflecting of the number of responders at each point on the scale. Responders agree that recipient cells internalize EVs from different cell types through endosomal uptake and acidification, and that proteins on the EV surface are responsible for fusion events. Survey participants are not sure how frequent EV-cell fusion events are in vivo.
Membrane fusion and stability

In the context of EV uptake and function, it is important to define EV structural and functional stability. Structural stability is the tendency of an EV to remain intact over time and under different conditions. Functional stability is the retention of a particular effect. On questions of EV stability, over half (67%) of survey respondents agreed that current technologies for studying EVs are not adequate to measure both functional and physical stability of EVs (Figure 9). When asked how freeze-thaw cycles may affect EV stability, 50% felt that more must be learned about potentially detrimental effects (Figure 10).

What about the relationship between fusogenicity and stability? Is an EV that fuses with a cellular membrane inherently “unstable”? Here, the molecular composition is likely to define membrane stability and tendency to fuse. Although membranes are coated with sugars and proteins, it is the lipid composition that most heavily dictates thermodynamic favourability for fusion. In principle, all vesicle-cell membrane fusions are thermodynamically favourable. The barriers to fusion are however kinetic, which may be lowered in relation to lipid compositions. For example, the insertion of cholesterol influences curvature and fusion properties of small vesicles [101–103]. Cone-shaped phospholipids induce high curvature, while those of cylindrical shape are found in more planar membranes. Fusion is thermodynamically favourable for more curved vesicles, as it brings the vesicles to a lower energy state. Small vesicles have a higher curvature and tighter membranes, lending to a very high-energy state and a possible predisposition for fusion. Supporting this likelihood, a portion of synthetic small unilamellar vesicles fuses with each other given enough time [104,105]. Contrastingly, the recovery of EVs as small as 30–50 nm in diameter from biological and culture fluids suggests a certain stability of even small EVs or subsets thereof. EVs may be more likely to fuse after isolation than when in a complex mixture such as plasma. However, current techniques cannot easily distinguish between a large EV and a similarly-sized EV that formed by the fusion of several smaller vesicles. When asked about the relationship between EV size and stability, 50% of respondents believed that size has a large impact on physical stability (Figure 9). EV-cell fusion is thermodynamically favourable but high kinetic barriers prevent spontaneous membrane coalescence. Lowering kinetic barriers can alter lipid membranes, including increased bilayer curvature, and the presence of protein-based fusion catalysts.
The functional capacity of an EV is likely dependent on membrane protein topology. Overall, membrane protein composition appears to be heavily influenced by EV size, the cell type of origin and cellular activation state. One technique to study EV membrane composition is free radical incorporation or electron-dense lipid labelling. Incorporating free radicals in membrane samples can provide useful topological information on both the membrane and/or associated/integral proteins based on the preferential localization of the radical used [106,107]. On the other hand, using lipids containing radicals at different positions in the tail could help provide information about the transmembrane region itself [108]. Some new techniques to make pseudo-membranes containing differently shaped phospholipids can allow for further study of how composition can influence membrane curvature and fusion by using nuclear magnetic resonance (NMR) [109].

**Figure 9.** EV stability. Two questions regarding EV stability were administered in the post-workshop survey. For each question, participants’ answers are depicted horizontally on a Likert-scale from 0 to 10, with bubble size reflecting the number of responders at each point on the scale. While EVs are physically stable, most survey participants believe that current technologies need to be improved to simultaneously measure the functional and physical stability of EVs.

**Figure 10.** Storage of EVs. In the post-workshop survey, participants were asked to choose from five options whether or not they believe freeze-thawing causes damage to EVs. Responders agree that we do not know enough about how freeze-thawing affects EV stability, uptake, and functionality.
Many questions remain to be answered about EV functional stability: Is the physical structure or the encapsulated content most important? If the structure of an EV has been compromised, does that necessarily affect its carrier/delivery function? Also, does the presence or absence of cargo reciprocally influence EV stability?

Finally, it is worth noting that our knowledge on EV membrane interactions with inorganic nanostructures and surfaces is poor and fragmented, albeit of key importance for future EV processing and engineering technologies (e.g. colloidal gold nanoplasmonic assays [110], microfluidics/lab-on-chip applications [111], EV supported lipid bilayers [112]).

In vivo administration of EVs: how membrane components and associates affect distribution

One of the most alluring aspects of EVs is the potential for the delivery of therapeutic drugs/molecules, which requires an understanding of the biodistribution of EVs introduced to healthy and diseased organisms. When introducing EVs to in vivo models, many factors need to be considered, including dose, route of administration, source of the administered EVs, and techniques for assessing biodistribution (i.e. labelling).

An overwhelming majority (87%) of workshop survey respondents suggested that EV transfer experiments are highly time dependent, and that the in vivo

![Bioactivity of EVs](image-url)

**Figure 11.** Bioactivity of EVs. Seven questions regarding the bioactivity of EVs were administered in the post-workshop survey. For each question, participants’ answers are depicted horizontally on a Likert-scale from 0 to 10, with bubble size reflecting of the number of responders at each point on the scale. Responders believe that the use of EVs for in vitro transfer experiments is time-dependent, that dose–response studies are important, and that EVs have a greater functional impact in the local tissue environment. Survey participants are undecided on how to determine and identify bioactive EVs. The survey reveals the need for improved technology for the study of EV-cell fusion.
relevance is often unclear (Figure 11). Since the local physiological concentrations of EVs are often unknown and may change depending on disease state, dose-response studies to optimize EV concentrations for the creation of uptake profiles is critical; 90% of participants agreed (see also MISEV2018 [33]) on the importance of dose-response to establish any effect of EVs for both in vitro and in vivo studies (Figure 11).

The half-life of exogenously administered EVs in circulation has been reported to be relatively short (in the range of tens of minutes), so serial or differential dosing may be necessary and will likely require optimization. By increasing the half-life of EVs, for example, through PEGylation [113] or by incorporation of a “don’t eat me” signal such as CD47 [114], higher plasma and/or tissue levels may be reached.

Administration route (e.g. intraperitoneal (i.p.), tail vein, intramuscular, or interventricular injection or intranasal inhalation) can also influence EV biodistribution, and thereby the concentration that reaches the desired target. Subcutaneous injections lead to accumulation of EVs in the lymphatic system [115,116], while those injected directly into the tail vein are cleared by the liver and spleen [117,118]. These data are consistent with previous work in the field of synthetic nanomedicine, which indicate that the vast majority of injected nanoparticles aggregate in liver and spleen, with only very subtle accumulation in specific tissues [119,120].

The concept of “targeting” is perhaps somewhat misleading for EVs under normal conditions, necessitating careful descriptions [121]. Unlike cells, EVs cannot actively seek targets via signal gradients, reports of motility notwithstanding [122]. Instead, passive accumulation, which is mainly driven by EVs’ physiochemical properties, seems the likely dominant distribution mechanism, with “targeting” determined by different affinities for cells with which chance interaction occurs.

Nevertheless, in inflammatory conditions including certain cancers, injected nanoparticles may accumulate in inflamed tissue due to vascular leakiness [114]. For example, in vivo targeting of EVs to the heart is difficult because of the intact endothelial barrier; yet, if the tissue is infarcted, the chance of infiltration will increase due to vascular leakiness [123]. Similarly, EVs are more likely to enter the brain when it is inflamed [124], and EV accumulation within kidneys is significantly increased in animal models of acute kidney injury [125]. Nevertheless, only about 44% of Workshop survey respondents felt that EVs accumulate in cancerous tissue (Figure 11).

To study EV biodistribution, EV labelling or some other method is needed for tracking and visualization. Theoretically, a membrane labelling dye may largely disappear upon fusion, making it challenging to study functional EV biodistribution. An alternative approach might be to trace EV cargo, e.g. through measuring delivery of Cre recombinase mRNA or protein via EVs, using animals harbouring reporter systems such as a Cre-sensitive colour-switch reporter [126]. A clear recommendation stemming from the Workshop is the need for an improved methodology to study EV biodistribution.

**What is the physiological role of EVs in homeostasis and disease?**

While the field has not identified which is the most significant EV-related disease, cancer is the most heavily studied, and EVs have been strongly implicated in metastasis and the formation of tumour microenvironments. Other intensively studied pathologies include neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s disease, and prion diseases [127,128], as well as diabetes and acute phase responses. Understanding the basic physiological functions of EVs will allow for further exploration of their roles in homeostatic maintenance or disease dissemination. Another recommendation from this Workshop is the need for advanced animal models to study the physiological importance of EV-mediated cargo transfer between cells and tissue; these are required to conclude how EV-mediated communication impacts disease development. This is especially true when exploring the potential secondary effects of EVs. For example, EVs released from damaged lung can induce pulmonary hypertension when injected into healthy mice. However, these effects appear to be modulated by EV-induced alterations in bone marrow cells, which then promote pulmonary hypertension [129,130]. Furthermore, the field needs to establish guidelines for defining and/or concluding which EV subpopulations and associated cargo are involved in homeostatic maintenance and pathological responses. One approach is to screen EV populations before and after (patho)physiological stimulations/treatment regimens, with the subsequent utilization of techniques like RNA sequencing, proteomics, and lipidomics. Implementation of multi-omics and longitudinal cohorts can aid in enhancing the overall understanding of EV biology and composition and can serve as quality controls for EV subsets of interest.

**Technologies and strategies for studying EVs: considerations and limitations**

The results of the Pre-Workshop survey confirm that there remain many uncertainties and controversies in
the EV field. For example, do the results of EV-uptake experiments using cells cultured in 2D really reflect what occurs in vivo? Does fluorescent labelling of purified EVs lead to artefacts caused by aggregations of the dye? How does the curvature of the vesicle and the surface it binds to affect the fusion or function of the EV? Do current methodologies for isolation or enrichment alter the function of EVs and must we “live with” the current limitations in separation technology? What is the role of heterogeneity in EV function and what new tools are needed to assess EV heterogeneity? Some reasons why these questions have not yet been resolved include the relative youth of the EV field, a lack of robust tools and technologies for studying EVs, as well as the lack of proper reporting and consistent terminology in a largely heterogeneous approach to analysing EVs across the community.

Many of the most frequently cited “influential studies” highlighted in the pre-workshop survey related to characterizing EV subpopulations and developing novel technologies for studying EVs with single-particle sensitivity. The efforts of the Society to summarize and update the field with current knowledge were also appreciated by the citation of previous ISEV position papers. Participants also indicated the importance of standardization and reporting initiatives such as EV-TRACK.

The need for new technologies and methodologies was also evident from the verbatim feedback in the survey. There was a particular focus on the need for new or improved imaging techniques. Several applications of electron microscopy (EM) were suggested, including 3D scanning electron microscopy (3D-SEM) combined with labelling techniques such as APEX (a monomeric peroxidase that withstands EM sample preparation) and correlative light and electron microscopy (CLEM). Many EVs are below the diffraction limit of light, so super-resolution microscopy methods need to be developed further to visualize EVs with better resolution. Tracking of single EVs is challenging due to their small size and paucity of molecular content; imaging individual EVs could be enabled by the use of brighter tags such as tandem fluorescent proteins or SunTag. Improved techniques for quantifying the occurrence and effects of EV transfer, including in the in vivo setting, were raised as an important requirement in the field. Furthermore, there are other biophysical properties of EVs that should also be investigated, including stiffness, adhesiveness, aggregation and morphology. Techniques such as atomic force microscopy (AFM), scanning probe microscopy, cryoEM and neutron-scattering techniques could be used to measure these properties. A need for improved isolation and labelling of EVs was also reported in the survey. Taken together, these comments highlight the need for improved technologies in the EV field. This was also evident from the range of talks at the Workshop and the round-table discussions. The current “limitations” should be viewed as opportunities: new approaches combined with a greater understanding of EV biology will allow us to gain new insight into EV biology and begin to resolve some of the uncertainty in the field.

**Experimental issues with purification and characterization of EVs**

EVs are challenging to study due to their small size (mostly <1 µm diameter), heterogeneity and lack of discriminative markers. Although differential ultracentrifugation is the historical workhorse for EV isolation, it may introduce artefacts such as disruption of membrane topology, EV aggregation and decoration of EVs with other components present in the sample. Theoretically, filtration by gravity flow should be gentler, but pushing samples forcefully though a small-pored filter may, besides trapping EVs in the filter, also damage or break EV membranes. Altering properties of EVs during separation may also affect functionality. Other important questions to consider include: do our current separation techniques over-purify or select for more “stable” EVs? Are we removing important signalling molecules or cofactors from the supernatant when we remove EVs from their biological medium? How does the starting sample volume and type (i.e. the biological matrix in which the EVs are present) influence EV stability? Is one isolation technique better for certain biological sample types than another? Many of these questions still need to be resolved by basic analytical experimentation.

Likewise, the best practices for EV characterization, counting and sizing are still not universally agreed upon. When working with samples derived from mixed populations of cells, such as a biofluid or supernatant from mixed cultures, the limited knowledge of cell-specific EV markers makes identifying the cell of origin challenging. Ongoing multimodal research approaches should assist in the identification of tissue/cell-specific markers. There are also a range of methods for counting and sizing EVs, including nanoparticle tracking analysis (NTA), tunable resistive pulse sensing (TRPS), Raman spectroscopy, flow cytometry, single-particle interferometric reflectance imaging sensing (SP-IRIS) and electron microscopy. These vary in their accuracy,
resolution, strengths and weaknesses [133,135]. Unsurprisingly, the vast majority (90%) of survey responders agree that different measurement technologies are biased towards certain EV size ranges (Figure 12).

**Exploring current EV fluorescent labelling techniques**

Many experiments incorporate the use of fluorescent labels to visualize EV production, uptake, and biodistribution. Although there is currently no efficient pan-EV marker, many uptake studies utilize lipophilic dyes such as PKH and Bodipy. The mechanism of action of PKH is intercalating, with saturated acyl-chain lipids inserting into lipid-raft structures. While PKH does not form highly ordered micelles, it can form micelle-like structures if it is not below the critical micelle concentration [142]. Above this concentration, the properties can change and give rise to artefacts and background [142,143]. Bodipy is another popular dye which some groups prefer over PKH as there is reduced background and limited overlap with signals from EVs. Alternatives to lipophilic dyes include CFSE and maleimide-thiol coupling of dyes to EVs [144]. Interestingly, some labelling protocols recommend BSA to quench dye labelling of EVs. However, BSA may contain bovine EVs. Protocols for best EV labelling practices are needed to discern between labelled EVs, aggregates of dye, and label incorporated by contaminants such as those in BSA. Free dye controls are important, to show clearance of unbound dye, and that all fluorescent entities observed are EV-associated. Flotation gradients may assist with separation of labelled EVs from dye aggregates, but other contaminants may remain [143].

The majority (72%) of workshop participants concur that lipid dye experiments are unreliable unless the proper controls are used to discern between labelled EVs and aggregated dye (Figure 12). An endogenous method to label EVs by using an amphiphilic Near Infrared (NIR)-fluorescent probe, in which cells carry out the labelling prior to secretion of the EVs, has been recently proposed [145]. It does not require the use of

---

**Figure 12.** Current particle tracking technologies. Three questions regarding current particle tracking technologies were administered in the post-workshop survey. For each question, participants’ answers are depicted horizontally on a Likert-scale from 0 to 10, with bubble size reflecting of the number of responders at each point on the scale. Survey participants require improved, non-biased technologies for determining EV size. The use of lipid dye can cause experimental artefacts.
immuno-labels, reagents for conjugation reactions or chromatographic purifications.

Another strategy for the labelling of vesicles is via fluorescent tagging of EV proteins. For example, tagging of tetraspanin proteins such as CD63 or CD81 with fluorescent proteins such as GFP or mCherry allows EVs to be visualized and tracked. Innovative approaches in which pH-dependent tags are employed, have been used to visualize EVs following fusion of the MVB with the PM [146]. This approach depends on the acidic environment of the multivesicular body and a neutral environment outside the cell. Alternatively, tagging abundant fluorescent reporters with a degradation motif (degron) is a way to specifically label EVs and remove the reporter from the source cell, allowing the observation of autocrine interactions in vivo [35,59,147]. Issues that need to be considered for any protein-tagging approach include the half-life of the fluorescent tag, the brightness of the tag, the limits of resolution of the microscopy technique used, and the possibility that tagged EVs (or indeed dye-labelled EVs) may have altered cargo or function. Another issue is that the visualization of EVs that lack the fluorescently tagged protein would be “invisible” and would thus be missing from any analysis. In this respect, general EV membrane labelling using, for example, fluorescent proteins fused to farnesylation or palmitoylation signals may be preferred [148,149]. It is recommended that further work is undertaken to optimize and establish the best methodology for the fluorescent tagging or labelling of EVs.

Single-vesicle analysis techniques – where are we and what do we need?

The survey revealed that single-vesicle analysis techniques are one of the most frequently suggested technological advancements that are needed for the field, with high-resolution single-vesicle flow cytometry being particularly in demand, offering high-throughput analysis with a commonly available tool. Of note, 70–75% of EV researchers use flow cytometry (FC) for targeted phenotyping [150]. Almost every survey respondent (97%) valued the development of single-vesicle flow analysis for EVs below ~500 nm in diameter (Figure 13). A reliable and accurate EV-nanoflow technique with the use of specialized cytometers with higher scatter sensitivity to measure small particles would allow for profound advances in understanding both membrane composition and internal cargo through state-of-the-art sorting and subsequent analysis. Because the size of the majority of EVs is below the wavelength of visible light, the majority (68%) of survey respondents believe that fluorescent triggering in EV-flow cytometry allows for better resolution than scatter (Figure 14); however, since no EV-specific generic labelling strategy is available, other non-EV components (e.g. lipoprotein particles), cell debris and/or EV membrane fragments may also be detected. Furthermore, the small size of EVs renders them particularly prone to swarm effects often leading to erroneous interpretation of data, as many instruments are still not sensitive enough to detect such small particles.

Figure 13. Current opinion on EV-flow cytometry. In the post-workshop survey, participants were asked to choose between two options regarding the current status of applying flow cytometry to the study of EVs. Almost all responders to this question call for specialized equipment, reagents and expertise to characterize single EVs through flow cytometry.
Of significance, there still needs to be established the ideal fluorescent dye for fluorescent triggering which is capable of staining all EVs in a preparation. Depending on EV size, it is estimated that about 1–100 copies of a particular protein could be present on the EV surface [153]. This low number of proteins present on the EV surface may hamper the immune-detection by fluorescent antibodies of EVs or EV subsets. The development of brighter fluorophores, alternatives for fluorescent antibodies, as well as the ability to increase the signal-to-noise ratio by optimizing flow cytometers and settings for EV analysis will lead to improved single-EV detection.

Instead of labelling proteins on the EV surface, highly specific fluorescent lipid dyes may hold potential for fluorescent-based EV analysis. In that respect, proteins that bind different lipids can be useful to distinguish subpopulations of EVs and could be applied to the single-vesicle analysis, including flow cytometry [154]. Myristoylated alanine-rich C-kinase substrate (MARCKS) peptides [155,156] could also be of potential use to label vesicles based on membrane curvature. Ultimately, the combination of generic lipid dyes or lipid detection together with specific labelling of EVs with fluorescent antibodies or other reagents to label EV surface proteins offers new possibilities to define and eventually sort specific EV subpopulations. However, with multi-fluorescent approaches precautions should be taken for quenching effects due to the small surface area of the EV.

In general, every survey respondent (100%) agreed that the development of reagents, such as single-chain antibodies, aptamers, and less bulky fluorophores, is needed to improve the sensitivity of EV flow. (Figure 14).

Currently, high-resolution flow-cytometric single-EV analysis utilizes slow flow rates and although sorting of single EVs can be performed [151], long sort times and diluted samples result in a limited amount of sorted EVs, which restricts the possibilities for downstream analysis. Additionally, the purity of the sorted EV populations should be analysed and demonstrated by other methods and potential effects of the sorting process and subsequent sample processing on EV integrity should be evaluated.

Altogether, there is a growing awareness of the physical limitations of commonly used flow cytometers developed for cell analysis which are using different optics and laser configurations tuned for cellular analysis. However, the field is moving towards better instrumentation for flow cytometric analysis of EVs.
To make genuine leaps forward it is recommended that the EV field must adopt a more multidisciplinary approach, seeking expertise from specialists in other disciplines, including engineering, physics, imaging and chemistry. A biomimetic approach to studying EVs involves producing synthetic analogues. Survey participants had mixed views on current capabilities to engineer truly artificial EVs, with about one-third believing it is presently possible, and almost half (42%) thinking it is not (Figure 15), though this could be partly due to different interpretations of the term “artificial EVs”. Indeed, engineering EVs from biological sources is done routinely [159]. For example, EVs could be loaded with therapeutic cargo, like siRNAs or other drugs; successful delivery of this cargo can be used for therapeutic purposes or, as described above, to analyse EV uptake or distribution. One key point of discussion was the difference between intracellular and extracellular loading of engineered EV cargo. In other words, should artificial cargo be added by manipulating donor cells which then load the cargo for us, or should we isolate EVs and artificially insert (or add to the surface) cargo via experimental perturbations such as electroporation or pH-dependent opening? The choice of how to artificially load cargo in engineered EVs could affect the utilization of the cargo in recipient cells. Another way to engineer EVs is to alter the surface composition to potentially re-direct the bio-targeting of vesicles [160]. Whether a top-down approach (starting with native EVs and modifying them to see how this affects function) or a bottom-up approach (generating artificial EVs from purified components) is taken, a better understanding of membrane biology will enhance our ability to engineer, understand and use EVs.

Another area discussed in the Workshop was that the EV field can learn a great deal from the virology field. Enveloped virus morphogenesis, secretion, and entry into target cells are well understood and are likely to reflect, at least partly, EV biogenesis, target-cell contact, endocytosis, and cargo delivery processes. Enveloped viruses encode proteins that drive particle (vesicle) assembly in producer cells, and particle (vesicle) disassembly in target cells. There may be valuable dividends to searches for EV-associated proteins that are functionally similar to those operating in enveloped virus infections. The virology field could lend a great deal of information as to how to artificially design EVs to target specific cell types and develop assays to indicate delivery of RNA or protein into the cytosol. The same mechanisms utilized for viral RNA packaging may also participate in EV RNA packaging. Fostering collaborations with virologists should be encouraged as it will likely aid in understanding EV release and uptake pathways.

**What new techniques or experimental approaches do we need to study EVs?**

To fully understand EV biology, physiology, and pathology, the field needs more than just better...
labelling techniques and the ability to perform single-EV analysis; the recommendation from the Workshop is that a raft of new technological approaches is required. Unsurprisingly, almost all survey participants (97%) agree that new animal models and more relevant in vitro systems are needed to address questions about production and function of subsets of EVs (Figure 15).

Animal models may be a viable option for understanding the production of EV subsets (MVB biogenesis, transport to PM, fusion with the PM, and budding from the PM). Genetic manipulations to track the transfer and uptake of EVs within an animal [126] may address these questions. The use of zebrafish [95], Drosophila melanogaster [161–163], or C. elegans [35,59,164] as genetic model organisms to study EV biogenesis may initially be more useful than rodent models, and are gaining traction within the field [165].

When using in vitro experimental methods, the environment in which EVs are generated, i.e. single-cell readouts, 2D cell culture, or organoids, is important. Will the use of organoids provide a more realistic indication of what is occurring with EV production and cargo transport than other culture methods? Understanding how EVs interact within a three-dimensional structure may be more helpful and translatable than traditional culture methods and is a goal for the future.

**Reporting in EV studies**

There are many factors that need to be addressed and reported when performing EV work, and many of these are outlined in both the 2014 and 2018 MISEV reports [32,33]. Transparency is needed to help the field reconcile conflicting data from different laboratories. For example, some data suggest that the passage number of cells can strongly impact EVs in terms of number, cargo, and markers (e.g. CD63) [166], making it difficult to draw conclusions as to whether or not observed effects were due to experimental manipulations. If a certain cell type in question does require supplementation with FBS, how are EVs depleted from serum? Even a 24-h ultracentrifugation does not remove all of the bovine RNA present in FBS, potentially leading to artefactual results [167]. If a cell type can survive in the absence of FBS, how does serum-starvation change cellular RNA profiles or influence assay readouts? Additionally, by culturing cells in serum-free conditions, clonal populations are being selected for survival, which could heavily influence experimental outcomes of downstream assays. This is also highly relevant to experiments performed using clonal cell lines generated by CRISPR/Cas9-mediated genome engineering. It is also important to understand the normal physiology of the cells being utilized for experiments prior to...
perturbing them. Careful experimental design is required when attempting to recapitulate a disease within a dish. Additionally, more primary cell work is required, as cell lines can behave in a dissimilar manner [168]. Overall, critical evaluation of how model systems reflect actual biology is essential. To identify large-scale, significant results, experimental consistency is key. We must strive to encourage and ensure high replicability and reproducibility within the field, which depends on critical evaluation of the consistency across experiments and detailed reporting.

**The future of EV therapeutics**

A major question in EV therapeutics is under what conditions the FDA, EMA and other regulatory agencies will approve therapeutic use of EVs. The clinical requirements for EV therapeutics and assays must be achieved before approval can be granted [169]. Cell-based therapies have been approved, so there is hope for EVs in the future. Future implementation of these therapies will focus heavily on the safety to biotherapeutic ratio. There is a strong feeling in the EV community that regulatory agencies will eventually support the use of EV therapeutics. How such agencies would categorize EVs also needs to be considered; i.e. will EVs be considered cell-like agents, or pharmaceutical agents? While the origin of cell culture-derived EVs is clear, the mechanism by which they convey function *in vivo* remains unknown. Another consideration is that we still do not isolate a pure homogenous population of vesicles; EV heterogeneity is an important problem/opportunity for the field [170,171]. A challenge for the therapeutic use of EVs is, therefore, the ability to purify the vesicles effectively enough. Thus, further work on the fundamental cell biology of EVs is essential to realize their therapeutic potential [172].

**Conclusion**

EV research is rapidly advancing, but many unanswered questions remain regarding basic EV biology and mechanisms of action. The primary goal of this workshop was to gauge the field’s understanding of the role of membranes in EV biogenesis, uptake/fusion, and the types of technologies needed to study these events. Through focused discussions and surveys administered to Workshop participants, considerable gaps in knowledge were identified and outline substantial opportunities for future research.

The field generally agrees that there are two main EV biogenesis pathways, which give rise to distinct EV subpopulations (exosomes and MVs). Despite this, many participants pointed out that we do not currently possess the technology to discern these vesicles from one another once they have entered the extracellular space. Gaining a better understanding of the fundamental properties of EV biogenesis, including the role of varying molecular components and changes in membrane topology during EV formation will undoubtedly aid in developing techniques to differentiate EVs derived from the endocytic pathway versus those shed from the plasma membrane. Other major considerations that have yet to be addressed are the energetic requirements needed for EV biogenesis, how various stimuli alter the activation of these mechanisms, and whether these mechanisms are conserved across cell types and species.

There remain many unanswered questions regarding the basic mechanisms by which EV-cell interactions occur; however, it is likely that these communications necessitate surface molecules present on both EVs and cells. Whether a predominant mechanism (i.e. signalling at the cell surface, endocytosis, or membrane fusion) presides and the level of specificity by which these interactions occur has yet to be determined. The impact of other factors that may influence EV-cell interactions including experimental timing, pH, temperature, membrane composition, EV concentration and stability, and the presence/absence of extracellular matrix all requires further investigation. The cellular consequences of these interactions are heavily understudied; basic knowledge as to how and where EV cargo is unloaded into cells, and the role of EVs in homeostasis has not yet been elucidated. As EVs are being considered as potential therapeutics, *in vivo* administration and biodistribution studies are now widely conducted. When designing these essential experiments, special considerations for the route of administration, how to best assess/measure biodistribution and careful data interpretation are required.

Development of new techniques for isolating and studying EVs is crucial for advancing the field. Indeed, differential ultracentrifugation, the current gold standard for EV isolation, may unintentionally introduce artefacts and change the inherent properties of the isolated particles. Similarly, the quantification and characterization of isolated vesicles using popular methodologies like nanoparticle tracking analysis may also generate biased or inaccurate data. Despite the great potential of fluorescent labels and dyes for studying EVs, there are numerous shortcomings associated with current products, and implementation of proper controls is often overlooked in the experimental design. Single-vesicle analysis tools are some of the most sought-after technological advancements in the field.
and are indeed on the horizon. Regardless of the currently available technologies, one of the most important things scientists can do for the study of EVs is to provide transparent reporting in their publications to allow for data replication and proper interpretation. It is hoped that by providing this summary of where consensus is present (or lacking) along with the recommendations for future work that this ISEV position paper will provide a supporting framework for the field to move forward.

Acknowledgments

The authors would like to thank J. Woodland Pomeroy (Johns Hopkins University) for facilitating all aspects of the planning and execution of the workshop. The Workshop Organizing Committee consisted of Kenneth W. Witwer (Chair; Johns Hopkins University), Norman J. Haughey (Johns Hopkins University), Steven M. Jay (University of Maryland), Alicia Llorente (Oslo University Hospital), Vasiliki Machairaki (Johns Hopkins University), Nicole Noren Hooten (National Institute on Aging, National Institutes of Health), Jeanne Sisk (Johns Hopkins University), Marca Wauben (Universiteit Utrecht), and Hang Yin (Tsinghua University). Roundtable moderators were Daniel Anthony (University of Oxford), Paolo Bergese (University of Brescia), David Raul Francisco Carter (Oxford Brookes University), Jan Lötvall (University of Gothenburg), Matias Ostrowski (University of Buenos Aires), Jeanne Sisk (Johns Hopkins University), Pieter Vader (University Medical Center Utrecht), Roosmarijn E Vandenbroucke (VIB-UGent Center for Inflammation Research), Marca Wauben (Utrecht University), and Hang Yin (University of Colorado Boulder). Oral session chairs included Amrita Datta Chaudhuri (Johns Hopkins University), Yiyou Huang (Johns Hopkins University), Steven M. Jay (University of Maryland), Vasiliki Machairaki (Johns Hopkins University), Nicole Noren Hooten (National Institute on Aging, National Institutes of Health), Ashley E. Russell (Johns Hopkins University), and Zhiwei Wu (Nanjing University).

Disclosure statement

Wauben (MMHW) had a collaborative research agreement with BD Biosciences Europe, Erembodegem, Belgium, to optimize analysis of EVs with the BD Influx.

Funding

KWW and AER are supported in part by US NIH R01 DA047807; KWW and YH were supported in part by US NIH R01 DA040385 and R56 AG057430, AS is supported by the National Science Foundation Graduate Research Fellowship under Grant No. 1746891; PB is supported by the National Interuniversity Consortium of Materials Science and Technology INSTM and the Center for Colloid and Surface Science (CSGI) through evFOUNDRY (Horizon 2020– Future and emerging technologies (H2020–FETOPEN), ID: 801367); UE is supported by NIH IK22HL126101-01A1; DWF and NNH are supported by the Intramural Research Program of the National Institutes of Health, National Institute on Aging; SMJ is supported by NIH (HL141611, GM130923); NSF (1750542); SK is supported by NIH R01 MH113645; GL is supported by Fondation ARC (PJA20171206453), Cancéropôle Ile-de-France (Emergence 2018) and French National Research Agency (ANR-10-IDEX-0001-02 PSL*, ANR-11-LABX-0043 and ANR-18-CE15-0008); AML is supported by the South-Eastern Norwegian Regional Health Authority, The Research Council of Norway, The Norwegian Cancer Society; QL is supported in part by the US NIH R01HL139496, R01ES029907, R01ES030302 and P30ES000002. VM is supported in part by grants from Maryland Stem Cell Research Fund (2016-MSCRFE-2739) and National Institutes of Health (R56 AG-057430); CM received support through NIH T32 OD011089. SS is supported by NIH/NHLBI: R01 HL124187, R01 HL140469, R01HL145644; NYSTEM: C32562GG; AHA:17GRNT33460554; Foundation Leducq: 17CV04; GvN and FV are supported by Fondation pour la Recherche Medicale (contract AJE20160635884), to GvN, the Fondation ARC pour la Recherche sur le Cancer fellowship (PJA 20161204808) to FJV; AVV is supported by BIO2015-72124-EXP. RT12018-095214-B-100 MICINN Ministerio de Ciencia Innovación y Universidades. INNIVAL/17/22 University Hospital Marqués de Valdecilla-IDIVAL; AMW is supported by Deutsche Forschungsgemeinschaft (DFG) grant WE5719/2-1; HY is supported by the National Key R&D Program of China Grand No. 2017YFA0505200, the National Natural Science Foundation of China Grand No. 20151300651 and No.20181371453, Beijing Outstanding Young Scientist program Grand No. BJWZYJH012019003013; DRFC is supported by BBSRC (BB/P006205/1), Cancer Research UK (A28052).

ORCID

Kenneth W. Witwer http://orcid.org/0000-0003-1664-4233
Paolo Bergese http://orcid.org/0000-0002-4652-2168
Emanuele Cocucci http://orcid.org/0000-0002-0088-9845
Steven M. Jay http://orcid.org/0000-0002-3827-5988
Nicole Noren Hooten http://orcid.org/0000-0002-1683-3838
Roosmarijn E. Vandenbroucke http://orcid.org/0000-0002-8327-620X
Ann M. Wehman http://orcid.org/0000-0001-9826-4132
Pieter Vader http://orcid.org/0000-0002-7059-8920

References


[58] Yeung V, Webber JP, Dunlop EA, et al. Rab35-dependent extracellular nanovesicles are required for


